Use of conjugate pneumococcal vaccine by United Kingdom neonatal intensive care units [2]

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 90, Issue 2, 2005, Pages

  Moss, S J ^a   Fenton, A C ^a   Gennery, A R ^b  

^a ROYAL VICTORIA INFIRMARY   (United Kingdom)

^b NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE;

CHRONIC LUNG DISEASE; CONSENSUS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG UTILIZATION; HEALTH SURVEY; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOGENICITY; INFECTION PREVENTION; INFECTION RISK; LETTER; NEWBORN INTENSIVE CARE; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; STREPTOCOCCUS INFECTION; UNITED KINGDOM;

GESTATIONAL AGE; GREAT BRITAIN; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE UNITS, NEONATAL; MENINGOCOCCAL VACCINES; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 14744304513     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2004.061911     Document Type: Letter

References (5)

1. Koskela M, Leinonen M, Häivä V, et al. First and second dose antibody responses to pneumococcal polysaccharide vaccine in infants. Pediatr Infect Dis 1986;5:45-50.
2. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
3. Chief medical Officer. Pneumococcal vaccine for at-risk under 2 year olds. http:// www.doh.gov.uk/cmo/cmo0201.htm.
4. Shinefield H, Black S, Ray P, et al. Efficacy, immunogenicity and safety of heptavalent pneumococcal conjugate vaccine in low birth weight and preterm infants. Pediatr Infect Dis J 2002;21:182-0.
5. Choo S, Zhang Q, Seymour L, et al. Primary and booster salivary antibody responses to a 7-valent pneumococcal conjugate vaccine in infants. J Infect Dis 2000;182:1260-3.